

West Virginia Pharmacy Services



Drug Utilization Review

4th Quarter 2024

Prepared by : **gainwell**



DUR Quarterly Overall Summary Report
Report Period from 10/01/2024 thru 12/31/2024

WVDRGS044

Categories	4th Qtr 2024	4th Qtr 2023	% Change
Total Paid Amount	\$245,069,323.92	\$237,715,092.82	3.09
Eligible Members	462,483	520,644	-11.17
Utilizing Eligibles	242,926	260,448	-6.73
Total # Prescriptions	2,017,554	2,132,099	-5.37
Cost per Utilizing Member	\$1,008.82	\$912.72	10.53
Average # Prescriptions per Utilizer	8	8	0.00
Average Cost per Prescription	\$121.47	\$111.49	8.95
# Generic Prescriptions	1,756,572	1,821,556	-3.57
% Generic Prescriptions	87	85	2.35
Total Cost - Generics	\$36,416,100.34	\$37,155,382.89	-1.99
Average Generic Prescription Cost	\$20.73	\$20.40	1.64
Average Days Supply - Generics	31	31	0.00
# Brand Prescriptions	260,982	310,543	-15.96
% Brand Prescriptions	12.00	14.00	-14.29
Total Cost - Brand	\$208,653,223.58	\$200,559,709.93	4.04
Average Brand Prescription Cost	\$799.49	\$645.84	23.79
Average Days Supply - Brand	25	24	4.17
Rebates Collected	\$160,933,293.50	\$234,284,410.66	-31.31



WVDRGS050

Top 25 Therapeutic Classes By Prescription Count

Report Period from 10/01/2024 thru 12/31/2024


Reporting Months (4th Quarter) 10/01/2024 - 12/31/2024

Rank	Therapeutic Class	Therapeutic Class Code	Prescription Count	% of Total Prescription Count	Amount Paid
1	ANTICONSULSANTS	H4B	97,500	4.80	\$4,406,136.01
2	OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	H3W	92,849	4.60	\$22,059,603.96
3	SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	H2S	78,278	3.80	\$911,174.75
4	PROTON-PUMP INHIBITORS	D4J	64,103	3.10	\$1,010,164.86
5	ANTIHIISTAMINES - 2ND GENERATION	Z2Q	64,064	3.10	\$857,482.40
6	BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	B6W	54,927	2.70	\$2,093,489.61
7	PENICILLIN ANTIBIOTICS	W1A	53,969	2.60	\$736,771.40
8	ANTIHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB (STATINS)	M4D	53,001	2.60	\$634,857.81
9	NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE ANALGESICS	S2B	51,116	2.50	\$670,401.31
10	VITAMIN D PREPARATIONS	C6D	45,801	2.20	\$447,801.20
11	GLUCOCORTICIDS	P5A	45,609	2.20	\$1,110,541.07
12	BETA-ADRENERGIC BLOCKING AGENTS	J7C	39,034	1.90	\$531,315.28
13	ANTIHIISTAMINES - 1ST GENERATION	Z2P	38,300	1.90	\$505,002.50
14	ANTIPIYCHOTIC,ATYPICAL,DOPAMINE,SEROTONIN ANTAGNST	H7T	37,084	1.80	\$5,570,457.77
15	SKELETAL MUSCLE RELAXANTS	H6H	32,036	1.60	\$403,353.73
16	ANTIEMETIC/ANTIVERTIGO AGENTS	H6J	30,867	1.50	\$453,102.13
17	ANTIHYPERTENSIVES, ACE INHIBITORS	A4D	29,051	1.40	\$336,142.58
18	SEROTONIN-NOREPINEPHRINE REUPTAKE-INHIB (SNRIS)	H7C	28,375	1.40	\$454,128.49
19	TX FOR ATTENTION DEFICIT-HYPERACT (ADHD)/NARCOLEPSY	H2V	27,638	1.40	\$3,238,894.65
20	MACROLIDE ANTIBIOTICS	W1D	27,217	1.30	\$418,307.61
21	ANTI-ANXIETY DRUGS	H2F	26,977	1.30	\$348,164.17
22	THYROID HORMONES	P3A	26,883	1.30	\$491,388.14
23	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	J5B	26,530	1.30	\$2,500,895.54
24	NASAL ANTI-INFLAMMATORY STEROIDS	Q7P	26,436	1.30	\$712,950.94
25	LEUKOTRIENE RECEPTOR ANTAGONISTS	Z4B	25,727	1.30	\$322,192.31
Totals:			1,123,372	54.90	\$51,224,720.22

WV POS Quarterly Drug Class Review Top 12 by Rx Count

Reporting Period From: 10/01/2024 - 12/31/2024

Reporting Months (4th Quarter): 10/01/2024 - 12/31/2024



Amount Paid	
ANTICONSULSANTS	\$4,406,136.01
OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	\$22,059,603.96
SELECTIVE SEROTONIN REUPTAKE INHIBITOR (SSRIS)	\$911,174.75
PROTON-PUMP INHIBITORS	\$1,010,164.86
ANTIHISTAMINES - 2ND GENERATION	\$857,482.40
BETA-ADRENERGIC AGENTS, INHALED, SHORT ACTING	\$2,093,489.61
PENICILLIN ANTIBIOTICS	\$736,771.40
ANTHYPERLIPIDEMIC-HMGCOA REDUCTASE INHIB(STATINS)	\$634,857.81
NSAIDS, CYCLOOXYGENASE INHIBITOR TYPE ANALGESICS	\$670,401.31
VITAMIN D PREPARATIONS	\$447,801.20
GLUCOCORTICIDS	\$1,110,541.07
BETA-ADRENERGIC BLOCKING AGENTS	\$531,315.28



WVDRGS029

Top 25 Therapeutic Classes by Amount Paid

Report Period from 10/01/2024 thru 12/31/2024


Reporting Months (4th Quarter): 10/1/2024-12/31/2024

Rank	Therapeutic Class	Therapeutic Class Codes	Amount Paid	% of Total Amount Paid	Prescription Count
1	OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	H3W	\$22,059,603.96	9.00	92,849
2	ANTIHYPERGLYCINEMIC, INCRETIN MIMETIC (GLP-1 RECEPTOR AGONIST)	C4I	\$21,769,894.06	8.90	24,519
3	ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	S2J	\$17,968,228.86	7.30	2,089
4	ANTIHYPERGLYCEMIC-SODIUM/GLUCOCOTRANSPORT2 (SGLT2) INHIBITOR	C4D	\$9,372,245.61	3.80	11,315
5	CYSTIC FIBROSIS-CFTR POTENTIATOR-CORRECTOR COMBIN.	B0F	\$7,735,198.74	3.10	304
6	ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	V1Q	\$6,978,908.84	2.80	484
7	ANTIPSYCHOTIC, ATYPICAL, DOPAMINE, SEROTONIN ANTAGONIST	H7T	\$5,570,457.77	2.30	37,084
8	INSULINS	C4G	\$5,204,486.30	2.10	21,220
9	DIRECT FACTOR XA INHIBITORS	M9V	\$5,196,737.33	2.10	7,396
10	ANTIPRURITIC AGENTS, SYSTEMIC	L1A	\$4,701,222.28	1.90	536
11	ARV-NUCLEOSIDE, NUCLEOTIDE RTI, INTEGRASE INHIBITORS	W5X	\$4,573,822.98	1.90	1,242
12	ANTICONVULSANTS	H4B	\$4,406,136.01	1.80	97,500
13	BETA-ADRENERGIC AND GLUCOCORTICOID COMBO, INHALED	B63	\$4,382,114.44	1.80	18,940
14	HEPATITIS C VIRUS- NS5A AND NS3/4A INHIBITOR COMB	W0E	\$4,220,311.96	1.70	332
15	INTERLEUKIN-4 (IL-4) RECEPTOR ALPHA ANTAGONIST, MAB	V4D	\$3,468,313.62	1.40	892
16	ANTIPSYCHOTIC-ATYPICAL, D3/D2 PARTIAL AG-5HT MIXED	H8W	\$3,446,681.52	1.40	2,608
17	DIABETIC SUPPLIES	Y9A	\$3,295,089.10	1.30	8,342
18	TX FOR ATTENTION DEFICIT-HYPERACT (ADHD)/NARCOLEPSY	H2V	\$3,238,894.65	1.30	27,638
19	HUMAN INTERLEUKIN 12/23 (IL-12/13) INHIBITORS, MAB	Z2U	\$2,961,905.35	1.20	113
20	HEMOPHILIA TREATMENT AGENTS, NON-FACTOR REPLACEMENT	M0P	\$2,736,033.03	1.10	77
21	HEP C VIRUS-NS5B POLYMERASE AND NS5A INHIB. COMBO.	W0B	\$2,721,862.51	1.10	377
22	ANTICHOLINERGICS, ORALLY INHALED LONG ACTING	B61	\$2,670,277.09	1.10	4,919
23	ANTIPSYCHOTICS, ATYP, D2 PARTIAL AGONIST/5HT MIXED	H7X	\$2,622,219.05	1.10	13,489
24	ADRENERGICS, AROMATIC, NON-CATECHOLAMINE	J5B	\$2,500,895.54	1.00	26,530
25	ANTIMIGRAINE PREPARATIONS	H3F	\$2,300,490.61	0.90	11,233
Totals:			\$156,102,031.21	63.40	412,028

Top 12 Therapeutic Classes by Amount Paid

Reporting Months 4th Quarter: 10/1/2024-12/31/2024

Reporting Months (4th Quarter): 10/1/2024-12/31/2024



Prescriptions

OPIOID WITHDRAWAL THERAPY AGENTS, OPIOID-TYPE	92,849
ANTIHYPERGLY,INCRETIN MIMETIC(GLP-1 RECEP.AGONIST)	24,519
ANTI-INFLAMMATORY TUMOR NECROSIS FACTOR INHIBITOR	2,089
ANTIHYPERGLYCEMIC-SOD/GLUC COTRANSPORT2(SGLT2) INH	11,315
CYSTIC FIBROSIS-CFTR POTENTIATOR-CORRECTOR COMBIN.	304
ANTINEOPLASTIC SYSTEMIC ENZYME INHIBITORS	484
ANTIPSYCHOTIC,ATYPICAL,DOPAMINE,SEROTONIN ANTAGNST	37,084
INSULINS	21,220
DIRECT FACTOR XA INHIBITORS	7,396
ANTIPSORIATIC AGENTS,SYSTEMIC	536
ARV-NUCLEOSIDE,NUCLEOTIDE RTI,INTEGRASE INHIBITORS	1,242
ANTICONVULSANTS	97,500


Pharmacy Generic Utilization Summary by Amount Paid

Reporting Month 4th Quarter: 10/1/2024-12/31/2024

Reporting Months (4th Quarter): 10/1/2024-12/31/2024

Generic Utilization Summary

by Amount Paid



	BNG	\$167,444,448	68.2 %
	BWG	\$41,320,270	16.8 %
	GEN	\$36,730,203	15.0 %
Total		\$245,494,922	100.0 %

BNG = Brand With no Generic Available


BWG = Brand Dispensed when Generic Available

GEN = Generic

Pharmacy Generic Utilization Summary By Number Of Prescriptions

Report Period from 10/01/2024 thru 12/31/2024

Reporting Months (4th Quarter): 10/1/2024-12/31/2024




BNG = Brand With no Generic Available

BWG = Brand Dispensed when Generic Available

GEN = Generic

Pharmacy DUR Savings - QUARTERLY
Report Period from 10/01/2024 thru 12/31/2024

Reporting Months (4th Quarter) : 10/1/2024 - 12/31/2024



Code	Description	Amount Saved	% of Savings
DD	Drug-Drug Interactions	\$1,219,510.18	2.00
ER	Early Refill	\$30,773,430.48	61.00
HD	High Dose	\$969,950.00	2.00
ID	Ingredient Duplication	\$1,868,631.49	4.00
LR	Late Refill	\$0.00	0.00
PG	Pregnancy Precaution	\$295,306.86	1.00
TD	Therapeutic Duplication	\$15,333,564.82	30.00
Totals:		\$50,460,393.83	100.00